AstraZeneca taps Alteogen in deal worth more than $1.3B to make subcutaneous cancer drugs
AstraZeneca is betting roughly $1.35 billion on Korean biotech Alteogen to help develop under-the-skin versions of multiple oncology therapies.
The British pharma will license ALT …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
